Pharmacological treatment of erectile dysfunction.
There is growing evidence that the field of pharmacotherapy, particularly oral drugs, will be dominant in the future management of sexual dysfunction. Basic research has led to the understanding of the intracellular mechanisms that control penile smooth muscle contractility and therefore erection, opening a vast area for pharmacological intervention. Moreover, the importance of central neurohormonal mechanisms has made these pathways the target for new centrally acting drugs. Given these trends most patients suffering from erectile dysfunction will respond to pharmacological agents in the not so distant future.
Moncada Iribarren
I
I
Unidada de Urologicay Andrologia, Hospital Ruber Internacional, Madrid, Spain.
Sáenz de Tejada
I
I
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000527:Alprostadil / Q000627:therapeutic use; D001058:Apomorphine / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009126:Muscle Relaxation / Q000187:drug effects; D010208:Papaverine / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D014665:Vasodilator Agents / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D018491:Dopamine Agonists; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate; D010208:Papaverine; D000527:Alprostadil; D001058:Apomorphine; D010646:Phentolamine